A detailed history of State Of New Jersey Common Pension Fund D transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, State Of New Jersey Common Pension Fund D holds 49,177 shares of HALO stock, worth $2.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
49,177
Previous 78,540 37.39%
Holding current value
$2.8 Million
Previous $3.2 Million 19.44%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$37.81 - $52.4 $1.11 Million - $1.54 Million
-29,363 Reduced 37.39%
49,177 $2.57 Million
Q3 2023

Nov 08, 2023

SELL
$36.46 - $44.03 $112,187 - $135,480
-3,077 Reduced 3.77%
78,540 $3 Million
Q4 2021

Jan 31, 2022

SELL
$31.82 - $40.75 $80,281 - $102,812
-2,523 Reduced 3.0%
81,617 $3.28 Million
Q3 2021

Oct 27, 2021

BUY
$38.47 - $46.42 $147,994 - $178,577
3,847 Added 4.79%
84,140 $3.42 Million
Q2 2021

Jul 23, 2021

BUY
$38.84 - $51.31 $5,554 - $7,337
143 Added 0.18%
80,293 $3.65 Million
Q1 2021

Apr 27, 2021

SELL
$39.51 - $51.45 $631,685 - $822,582
-15,988 Reduced 16.63%
80,150 $3.34 Million
Q4 2020

Feb 03, 2021

SELL
$25.81 - $43.62 $118,416 - $200,128
-4,588 Reduced 4.55%
96,138 $4.11 Million
Q3 2020

Oct 27, 2020

SELL
$25.74 - $29.63 $116,422 - $134,016
-4,523 Reduced 4.3%
100,726 $2.65 Million
Q2 2020

Aug 04, 2020

SELL
$16.25 - $26.81 $310,553 - $512,365
-19,111 Reduced 15.37%
105,249 $2.82 Million
Q4 2019

Jan 31, 2020

SELL
$14.93 - $19.53 $270,830 - $354,274
-18,140 Reduced 12.73%
124,360 $2.21 Million
Q3 2019

Oct 23, 2019

SELL
$15.2 - $17.69 $1.71 Million - $1.99 Million
-112,500 Reduced 44.12%
142,500 $2.21 Million
Q3 2017

Oct 25, 2017

BUY
$11.76 - $17.4 $3 Million - $4.44 Million
255,000
255,000 $4.43 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.93B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track State Of New Jersey Common Pension Fund D Portfolio

Follow State Of New Jersey Common Pension Fund D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

News

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.